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Objective. To analyze interval cancers among participants in a screening program for colorectal cancer (CRC) during four screening
rounds.Methods.The study population consisted of participants of a fecal occult blood test-based screening program fromFebruary
2000 to September 2010, with a 30-month follow-up (n = 30,480). We used hospital administration data to identify CRC. An
interval cancer was defined as an invasive cancer diagnosed within 30 months of a negative screening result and before the next
recommended examination. Gender, age, stage, and site distribution of interval cancers were compared with those in the screen-
detected group. Results. Within the study period, 97 tumors were screen-detected and 74 tumors were diagnosed after a negative
screening. In addition, 17 CRC (18.3%) were found after an inconclusive result and 2 cases were diagnosed within the surveillance
interval (2.1%).There was an increase of interval cancers over the four rounds (from 32.4% to 46.0%).When compared with screen-
detected cancers, interval cancers were found predominantly in the rectum (OR: 3.66; 95% CI: 1.51–8.88) and at more advanced
stages (𝑃 = 0.025). Conclusion. There are large numbers of cancer that are not detected through fecal occult blood test-based
screening. The low sensitivity should be emphasized to ensure that individuals with symptoms are not falsely reassured.
1. Introduction
Colorectal cancer (CRC) is the third most common cancer
and the fourth leading cause of cancer death worldwide.
About 1.36 million people are diagnosed annually with CRC,
and approximately 694,000 die from CRC annually [1].
Approximately 54% of CRC cases are diagnosed in developed
countries, and Europe represents one of the regions with the
highest rates in both incidence and mortality. As the sojourn
time for CRC is several years and a good prognosis is associ-
ated with diagnosis at early stage, screening has been imple-
mented in many countries [2]. The rationale behind cancer
screening programs is that early detection of cancer (before
symptoms arise) will reduce cause-specific mortality [3].
Compelling and consistent evidence from randomised con-
trolled trials shows that fecal occult blood test and flexible sig-
moidoscopy reduce CRCmortality [4, 5]. However, screening
also has the potential to harm. The relationship between
benefits and risks depends on the quality of screening [6, 7].
The monitoring of interval cancers (IC) is a crucial part
of the evaluation of a CRC screening program and a key
performance indicator. It provides a mechanism to evaluate
the likely impact of the program on CRC mortality in the
target population. IC are those that occur following a negative
screening episode, in the interval before the next invitation
to screening is due [8]. For fecal occult blood testing IC may
occur following a negative test, or following a positive test
result with a negative further assessment (colonoscopy) [9].
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Although IC are inevitable in a screening program, their
number should be as small as possible since a high proportion
would decrease screening effectiveness. Four plausible rea-
sons (missed polyps or CRC, incompletely resected polyps,
rapid progression of new polyps, and failure of biopsy to
diagnose a CRC that was present) have been proposed to
explain IC [10]. Two studies concluded that 50% to 75% of
interval CRC were likely the result of missed or incompletely
resected lesions and less than 30% were the result of rapidly
progressing lesions [11, 12].
Calculation of the IC rate also allows the calculation
of other performance indicators, such as the proportional
incidence and program sensitivity. The proportional inci-
dencemethod compares the incidence rate of IC in successive
periods after a negative screen with the expected incidence in
the absence of screening.Thedifference between the two rates
gives the number and proportion ofCRCwhose diagnosis has
been advanced by screening [13]. On the other hand, program
sensitivity (traditional method) compares screen-detected
CRC (SD) with IC. Such a method implies some degree of
overestimation of sensitivity, particularly when determined
at the first prevalence screening [14]. Proportional incidence
also has its limitations, mainly for the difficulty of estimating
underlying incidence in absence of screening (i.e., when a
cancer registry is lacking orwhen screening has been ongoing
since a long time) [14].
The aim of this study was to analyze IC among par-
ticipants in the screening program for CRC of L’Hospitalet
de Llobregat during four screening rounds. As a secondary
objective, program sensitivity was analyzed according to
demographic, screening, and tumor characteristics.
2. Material and Methods
2.1. Screening Procedure. In 2000, a biennial screening pro-
gram was launched in L’Hospitalet of Llobregat, an industrial
city in the metropolitan area of Barcelona (Catalonia, Spain).
The target population includes all men and women aged 50–
69 years who lived in the city (average of 65,000). Demo-
graphic data on this population is gathered from the Primary
Healthcare Information System. L’Hospitalet of Llobregat is
divided into 12 Basic Health Areas and screening invitations
are sent to eligible population assigned to each one of the
Basic Health Areas. Subjects who do not meet the inclusion
criteria for CRC screening are definitely or temporarily
excluded according to the following criteria: personal history
of CRC or adenomas, hereditary and familial CRC, inflam-
matory bowel disease, colonoscopy in the previous 5 years,
fecal occult blood test in less than 2 years, terminal disease,
and severe disabling condition. Subjects moving out of the
screening area or whose invitation letter is returned because
of an invalid mailing address are also excluded.
CRC screening criteria are assessed by means of a
questionnaire. When the questionnaire reports two or more
relatives with cancer, individuals are phoned through the
program to check the information and evaluate whether
he/she is eligible for CRC screening with fecal occult blood
testing or met the criteria for hereditary colorectal cancer.
If a high risk family history was confirmed, the individual
is excluded from the program and is referred to a genetic
counseling unit for a more detailed assessment. The program
allows the screening of individuals with a family history of
CRC or other noncolonic neoplasms as long as they do not
meet the criteria for hereditary cancer.
Since 2000, two screening test strategies have been used.
From the first to third rounds, a guaiac FOBT (gFOBT) was
used as the screening test (hema-screenTM, Immunostics
Inc., Ocean, NJ, USA). In the fourth round, the gFOBT was
offered to 50,227 individuals (eligible population assigned to
10 Basic Health Areas) and a quantitative immunochemical
test (OC-Auto Sampling Bottle 3, Eiken Chemical Co., Japan)
was offered to 12,707 (eligible population assigned to two
Basic Health Areas). The immunochemical test (FIT) was
initially introduced to the screening program to evaluate its
feasibility and acceptability. Briefly, participation was higher
among individuals who used the FIT (OR: 1.35; 95% CI: 1.27–
1.42). Detection rates for adenomas and cancer were also
higher for the FIT, highlighting the detection rate for high-
risk adenomas (26.7‰ versus 3.0‰). The positive predictive
value for high-risk adenomas was quite similar (45.0% and
46.9% in the FIT and gFOBT, resp.) [15]. As a result, FIT
remained the only strategy for further screening rounds (fifth
round and onwards).
Participants with gFOBT collected six fecal samples (two
samples from three separate bowel movements). The gFOBT
uses a chemical indicator that shows a color change in the
presence of blood. The possible results of the gFOBT were
(a) weakly positive: one to four positive samples. Those
participants with a weakly positive result were asked to
perform a second gFOBT and, if any sample was positive,
were offered colonoscopy without further testing. In contrast,
if all six samples were negative, a third gFOBTwas requested;
(b) spoilt kit/technical failure: laboratory was unable to
analyze the kit. The most common reason for a rejected
kit was that the information provided with the kit was not
complete. Those participants who refused to repeat the test
after a weak positive or a spoilt kit/technical failure were
coded with an indeterminate gFOBT result; (c) negative: zero
out of six positive samples; (d) strongly positive: five or six
positive samples.
On the other hand, participants with FIT collected one
sample (approximately 10mg of feces) which was added
to 2mL buffer. A 100 ngHb/mL cut-off (20mgHb/g feces)
was used as threshold for test positivity. Tests were assayed
generally on the day of receipt in the laboratory on one of
two automated clinical analyzers (OC-Sensor Micro or OC-
Sensor Diana). Samples were at 2∘–8∘C if not analyzed on the
day of receipt and then allowed to warm to room temperature
for the assay. Each sample was analyzed once.The upper limit
of the analytical working range for the fecal Hb concentra-
tionmeasurements was 1,000 ngHb/mL buffer (200mgHb/g
feces); samples with concentrations greater than this were not
diluted and not reassayed. When laboratory was unable to
analyze a test (spoilt kit or technical failure), the participant
was asked to repeat the FIT. If she/he refused, then the final
test result was coded as an indeterminate.
All participants with a positive test result were advised
to have colonoscopy. Subjects with no colorectal lesions
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detected in the colonoscopy are invited for screening again
after 10 years (if they are still within the target age group).
2.2. Study Population. The study population consisted of
participants of aCRC screening program fromFebruary 2000
to September 2010, with a minimum of 30-month follow-up
(𝑛 = 30,480).The period of study included four rounds of the
CRC screening program.
2.3. Data Collection and Variables. The CRC screening
program information system included data on individual
identification, age, gender, participation, appointment dates,
screening test (guaiac or immunochemical), final screen-
ing test results (positive, negative, or indeterminate), and
colonoscopy results (negative, precursor lesions, and CRC).
We used hospital administration data (minimum data set
(MDS)) to identify CRC. A SD was defined as an invasive
CRC diagnosed at colonoscopy triggered by a final positive
screening test result. On the other hand, IC was defined as
an invasive CRC diagnosed following a negative screening
episode and prior to the next scheduled screening examina-
tion. The next scheduled screening examination was defined
to be 30 months after the previous screen. Screening interval
was 24months; however, it should be considered adequate up
to 30 months (acceptable delay because of organizational and
management issues). Our screening programwas launched as
a pilot program and was considered an established program
by the third round.Themedian time between invitations was
33months (higher in the earlier rounds and descending in the
subsequent rounds).
Electronic medical records of the individuals identified
as being diagnosed for CRC were revised to gather tumor
characteristics, for instance, the anatomic pathology result
of the cancerous lesion and the extension study. CRC were
staged according to the tumor-nodal-metastasis (TNM) stag-
ing system and classified as early (TNM I/II) or late (TNM
III/IV) stage. Tumor site was grouped in three categories:
proximal defined as the region of the colon up to and
including the splenic flexure, distal including the descending
and sigmoid colon, and rectum.
Patients were classified into 4 groups according to par-
ticipation in the screening program: (1) individuals with
CRC diagnosed by screening; (2) individuals with a negative
screening result and CRC diagnosed prior to further screen-
ing round; and (3) individuals with an incomplete screening
process: (a) indeterminate test, (b) screenees with a positive
test who did not attend the colonoscopy and were diagnosed
during the interval as they became symptomatic; (4) indi-
viduals clinically diagnosed with CRC after 30 months of
their last screening (mainly nonattenders in further screening
rounds).
The program sensitivity was expressed as the number of
SD divided by both SD and IC following a normal screen or
assessment (traditional method).
The study protocol was approved by the Clinical Research
Ethics Committee of the Bellvitge University Hospital and all
involved parties followed the ethical requirements set forth
in the Spanish Organic Law on Protection of Personal Data
(15/1999 of December 13).
Table 1: Last screening result according to the test used (gFOBT or
FIT)‡ from 2000 to 2010.
gFOBT FIT
𝑛 % 𝑛 %
Negative test result 24,072 93.1 4,281 92.7
Indeterminate test result 1,003 3.9 50 1.1
Positive test result 787 3.0 287 6.0
Positive test with no further assessment∗ 58 0.2 9 0.2
Negative colonoscopy result 368 1.4 105 2.3
Low-risk adenoma 48 0.2 24 0.5
High-risk adenoma 225 0.9 122 2.6
CRC 77 0.3 20 0.4
Overall 25,862 4,618
‡gFOBT was the only screening test used in 1st–3rd round. For the fourth
round the gFOBT was offered to individuals in 10 Basic Health Areas and
the FIT was offered to individuals in two Basic Health Areas; ∗11 individuals
using gFOBT and 7 individuals using FIT were not referred to further
assessment because they had a recent colonoscopy.
2.4. Statistical Analysis. Adescriptive analysis of all screenees
diagnosedwith CRCwas carried out. Program sensitivity was
calculated according to demographic, screening, and tumor
characteristics.
Factors associated with ICwere analyzed usingmultivari-
ate logistic regression models. The variables included in the
multivariate analysis were gender, age, number of screens,
tumor site, and CRC stage. The results were expressed as
odds ratios (OR) with 95% confidence intervals (95% CI).
Differences were considered statistically significant when𝑃 <
0.05. All analyses were performed using R statistical software
(R Foundation for Statistical Computing, Vienna, Austria).
3. Results
Within the study period, 301 CRC were diagnosed in the
screened population (Figure 1). From those, 97 tumors were
detected during the screening process and 93 tumors were
diagnosed within 30months after the screening examination.
IC were diagnosed after a negative result in the screening
process (𝑛 = 74). In addition, 17 clinically diagnosed CRC
(18.3%) were found after an inconclusive result and 2 cases
were diagnosed within the surveillance interval (2.1%).
On the other hand, 111 CRC were found among symp-
tomatic individuals who did not attend screening in further
rounds; they were diagnosed with CRC after 30 months of
their last screening (range from31months to 12.2 years). From
those, 97 completed the screening process and had a negative
result.
Around 85% of the screenees used the gFOBT as the
screening strategy and the remaining 15% used the FIT
(Table 1). Regarding the clinically diagnosed tumors, eight
CRC were diagnosed in individuals who used the FIT and
half of the CRC were detected within 30 months after their
participation in the screening (Table 2).
The overall program sensitivity was 56.7% andwas higher
among men and young individuals (Table 3). Regarding
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Screening invitations
Fecal occult blood tests
60,424 negative test results
1,074 positive test 
results
72 low-risk adenomas 
97 colorectal cancers
1,834 indeterminate test results (incomplete screening process) 1,053 screenees 
347 high-risk adenomas 
Negative colonoscopy No colonoscopy Precursor lesions and screen-
detected colorectal cancers(incomplete screening process)
Clinically diagnosed
colorectal cancers
Clinically diagnosed 
colorectal cancers
Target population: 105,086 individuals
Invited population: 105,352 individuals
Tests performed among 30,480 screenees
28,353 screenees
n = 63,332
n = 258,494
n = 16
72 ≤ 30 month
95 > 30 months
n = 7
2 ≤ 30 months
5 > 30 months
n = 473
n = 67
∗ n = 516
Clinically diagnosed 
colorectal cancers
n = 4
2 ≤ 30 months
2 > 30 months
Clinically diagnosed 
colorectal cancers
n = 26
17 ≤ 30 months
9 > 30 months
∗
18 individuals were not referred to further assessment because they had a recent colonoscopy
Figure 1: Flowchart of the screening process from 2000 to 2010.
Table 2: Clinically diagnosed CRC among screening participants according to the test used (gFOBT or FIT) and their last screening result.
CRC diagnosed within ≤30 months CRC diagnosed >30 months
gFOBT FIT Overall gFOBT FIT Overall
Negative screening result∗ 71 3 74 95 2 97
Incomplete screening process 16 1 17 9 9
CRC after removal of an adenoma 2 2 3 2 5
Overall 89 4 93 107 4 111
∗It refers to a negative test or a positive test with a negative colonoscopy result.
the test used, sensitivity was 52.0% with gFOBT and 87.0%
with FIT.
Table 4 reports the results of the multivariate logistic
regressionmodel.When comparedwith SD, ICwere predom-
inantly in the rectum (OR: 3.66; 95% CI: 1.51–8.88). When
stratified by gender, no differences in cancer site were found.
This held for both SD and IC (Table 5).
Finally, differences in cancer staging were observed.
Individuals with a CRC diagnosed within 30 months after
their last screening had more advanced stages (𝑃 = 0.025).
4. Discussion
Theoverall program sensitivitywas relatively low.Ahigh false
negative rate should be emphasized to clinicians and patients
to ensure that those with symptoms are not falsely reassured
and slip through the diagnostic net [16].
Program sensitivity estimated in randomized clinical
trials ranged from 38% to 54% [17]. Some population-based
screening programs for CRC have also calculated program
sensitivity. Those programs using gFOBT reported an overall
sensitivity from 42.3% to 62.4% [18–22].
Otherwise, sensitivitywas higher in those programs using
FIT (from 71.3% to 85.6%) [23, 24]. It is worth mentioning
that program sensitivity decreases as more screening rounds
are included in the study. Although in our study FIT sensitiv-
ity was considerably higher compared to gFOBT sensitivity
(87.0% versus 52.0%, resp.), we have to be cautious due to the
small sample size of screenees using FIT.
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Table 3: Program sensitivity according to demographic, screening, and tumor characteristics.
Screen-detected CRC Interval CRC ≤30 months‡ CRC diagnosed >30 months‡ Program sensitivity∗
𝑛 (%) 𝑛 (%) 𝑛 (%) %
Gender
Men 65 (67.0) 47 (63.5) 62 (63.9) 58.0
Women 32 (33.0) 27 (36.5) 35 (36.1) 54.0
Age at diagnosis
50–59 29 (33.3) 13 (17.6) 5 (5.2) 69.0
60–69 45 (51.7) 54 (73.0) 32 (33.0) 45.5
≥70 23 (14.9) 7 (9.5) 60 (61.9) 76.7
Screening
First screening 53 (54.6) 26 (35.1) 58 (59.8) 67.1
Successive screenings 44 (45.4) 48 (64.9) 39 (40.2) 47.8
Last screening round
1 23 (23.7) 11 (14.9) 38 (39.2) 67.6
2 13 (13.4) 14 (18.9) 34 (35.1) 48.1
3 27 (27.8) 20 (27.0) 14 (14.4) 57.4
4 34 (35.1) 29 (39.2)† 11 (11.3)# 54.0
Number of screens
1 53 (54.6) 26 (35.1) 58 (59.8) 67.1
2 17 (17.5) 27 (36.5) 30 (30.9) 38.6
3 19 (19.6) 16 (21.6) 7 (7.2) 54.3
4 8 (8.2) 5 (6.8) 2 (2.1) 61.5
Tumor site∗∗
Proximal 23 (23.7) 15 (25.0) 28 (40.0) 60.5
Distal 56 (57.7) 20 (33.3) 24 (34.3) 73.7
Rectum 18 (18.6) 25 (41.7) 18 (25.7) 41.9
Tumor stage∗∗
I 39 (40.2) 9 (14.8) 14 (17.3) 81.3
II 18 (18.6) 17 (27.9) 27 (33.3) 51.4
III 30 (30.9) 28 (45.9) 27 (33.3) 51.7
IV 10 (10.3) 7 (11.5) 13 (16.0) 58.8
‡Only CRC detected in individuals with a negative result in their last screening were considered; ∗sensitivity expressed as the proportion of CRC diagnosed
during the screening divided by all CRC diagnosed among screening participants up to 30 months; ∗∗variables with missing values; †26 CRC diagnosed after
a negative gFOBT and 3 CRC diagnosed after a negative FIT; #9 CRC diagnosed after a negative gFOBT and 2 CRC diagnosed after a negative FIT.
Around 18% of CRC were identified in individuals who
did not complete the screening process because of an incon-
clusive FOBT or refusal of further assessment (colonoscopy).
Strategies aimed at eliminating or reduce inconclusive test
results should be implemented. In this way, both screening
quality and program sensitivity would improve.
Efforts in communicating the need for being screened
regularly should be made. One-third of CRC identified
among individuals who had ever participated in the CRC
screening program were diagnosed after 30 months of their
last screening. Once in a lifetime screening is not enough,
especially if the screening modality is FOBT. On the con-
trary, successive screening is needed to detect and prevent
CRC. The sojourn time (the period when a test can detect
asymptomatic disease) is being estimated in 2.2 to 4.9 years
for gFOBT [25, 26].
However, some of the CRC clinically diagnosed among
individuals after 30 months of their last screening could be
averted if they would have been invited within an adequate
screening interval. Time between invitations from the early
rounds (first and second screening round) was on average
36 months due to some management and organizational
concerns. By the third round, time between invitations was
acceptable.
Regarding factors associated with IC, differences in sen-
sitivity according to tumor site and cancer stage have been
found. We did not find differences in the IC according to
gender. However, some studies have shown higher IC rates
among women [21, 22, 27, 28].
Most of the studies have shown that IC were more
frequently located in the proximal colon [18, 22, 27]. Tazi et
al. found IC weremore likely to arise in the rectum compared
with SD [19].
Finally, our findings regarding IC being diagnosed at
more advanced stages are consistent with the literature [19,
20, 22, 27, 28].
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Table 4: Factors associated with clinically diagnosed CRC among individuals who ever participated in the screening program for CRC (≤30
months versus >30 months since their last screening).
Interval CRC ≤30 months Clinically diagnosed CRC >30 months
ORa 95% CI ORa 95% CI
Gender
Men 1 1
Women 1.02 (0.44–2.33) 1.94 (0.69–5.43)
Age at diagnosis∗ 1.03 (0.96–1.11) 1.38 (1.24–1.53)
Number of screens 1.24 (0.85–1.81) 0.55 (0.32–0.94)
Tumor site
Distal 1 1
Proximal 1.32 (0.51–3.39) 3.73 (1.21–11.51)
Rectum 3.66 (1.51–8.88) 3.48 (1.02–11.87)
Tumor stage
I 1 1
II 2.63 (0.86–8.04) 2.21 (0.61–8.07)
III 3.45 (1.39–8.30) 1.66 (0.51–5.43)
IV 2.80 (0.73–10.76) 4.86 (1.02–23.24)
ORa adjusted odds ratios derived from multivariate logistic regression models. Analysis was restricted to those individuals with a negative result in their last
screening that have been diagnosed with CRC later on and those who were diagnosed during the screening process. ∗Age at diagnosis was considered as a
continuous variable; the age range was 50–73 years for individuals with a CRC diagnosed within 30months after their screening and 55–80 years for individuals
who ever participated in the screening program and were diagnosed with CRC.
Table 5: Distribution of screen-detected and clinically detected CRC according to tumor site and gender.
Tumor site
Screen-detected CRC Interval CRC (≤30 months) Clinically diagnosed CRC >30 months
Men Women Men Women Men Women
𝑛 (%) 𝑛 (%) 𝑛 (%) 𝑛 (%) 𝑛 (%) 𝑛 (%)
Proximal 13 (20.0) 10 (31.3) 8 (19.5) 7 (36.8) 16 (37.2) 12 (44.4)
Distal 37 (56.9) 19 (59.4) 14 (34.1) 6 (31.6) 14 (32.6) 10 (37.0)
Rectum 15 (23.1) 3 (9.4) 19 (46.3) 6 (31.6) 13 (30.2) 5 (18.5)
Men versus women in screen-detected CRC: 𝜒2 = 3.34, 𝑃 = 0.19; men versus women in interval CRC (≤30 months): 𝜒2 = 2.26, 𝑃 = 0.32; men versus women
in clinically-diagnosed CRC >30 months: 𝜒2 = 1.20; 𝑃 = 0.55.
Among the strengths of this study it is worth mentioning
that it is the first study to report IC in a population-based
screening program for CRC in Spain. In addition, the length
of the study period allows estimating program sensitivity
in both prevalent and incident rounds. Most of the studies
aimed at analyzing IC have included only two rounds.
Some of the limitations of this study are related with
case ascertainment and completeness of cancer data. Interval
cancers should be ideally identified through a cancer registry.
Checking hospital discharge records may be very useful in
areas uncovered by a cancer registry as in our case. However,
such a method tends to ignore cases treated outside the
National Health System and/or having no hospitalization and
those who migrate to a different region. In our study, 85%
of CRC diagnosed in private hospitals could be identified.
However, there was some missing information regarding
tumor characteristics such as the cancer site or stage.
We could not perform a multivariate logistic regression
analysis stratified by the test used (gFOBT or FIT) because of
the small number of cases. However, as the FIT remained the
only one screening strategy by fifth round and onwards, we
will be able to evaluate FIT sensitivity and identify whether
there are differences according to demographic, screening,
and tumor characteristics.
As far as we know, only one study in Spain validated the
ability of hospital administration data set to detect incident
cases of CRC using a cancer registry as the gold standard and
measured agreement between the MDS and registration of
CRC [29]. The study population consisted of incident cases
of CRC in 2000 obtained from the cancer registry and cases
in theMDS of a public hospital for the same year. Around 2%
of CRC identified through the cancer registry did not require
hospitalization. The MDS detected 85% of the cases and the
main reason to not identify cases was differences regarding
the incidence date (12 out 13 cases that did not match were
found in 2001). We revised CRC from 2000 to 2013, so this
potential error should be minimized.
Another limitation is that we calculated the program
sensitivity using the traditional method and without taking
into account the CRC sojourn time. We could not calculate
proportional incidence because we do not have a cancer
registry that covers our screening area.However, the program
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sensitivity may be more easily interpretable than the pro-
portional incidence and is not dependent on the underlying
incidence of disease in the screened population.
4.1. Future Research. Further research is needed to discrimi-
nate IC due to a false negative screening result from interval
cancers de novo, with a rapid tumor growth. Recent biological
data have begun to suggest that a proportion of IC exhibits
altered biological features that may contribute to their rapid
development relative to those that are detected on screening
[30]. Thus, it remains necessary to further establish and
expand our understanding ofmolecular pathways involved in
IC tomodify and/or develop appropriate screening programs
and specific treatment options to combat this unique form of
CRC [31, 32].
Association of molecular features (i.e., BRAF and KRAS
mutations, CpG island methylator phenotype, and sporadic
microsatellite instability) with dietary and lifestyle factors
also needs to be explored [33, 34].
4.2. Methodological Issues for Benchmarking and Comparison
of IC. There is some variation regarding how IC are actu-
ally defined, identified, and reported in different programs.
Differences in definition, quantification, or completeness of
identification of IC between programs distort the underlying
differences in IC frequency and obscure interpretation of this
measure [35].
Operational definition and quantification method for
interval cancer are needed to eliminate or control some
sources of artefactual variation across programs. The accu-
racy of identification of interval cancer may potentially be
the largest source of error and discrepancy between programs
[35].
There are a few expert working groups that are making
efforts to that end (NHS Bowel Cancer Screening Program,
World Endoscopy Organization, Spanish Network of Cancer
Screening Programs) [36, 37]. Their aim is to define IC to
facilitate benchmarking and comparison of IC rates across
programs and regions. Incomplete follow-up in the screened
population and imprecise linkage between data sources are
the main limiting factors in the identification of IC.
5. Conclusion
There are large numbers of cancer that are not detected
through fecal occult blood test-based screening. Screening
programs using gFOBT should take into account that initia-
tives aimed at decreasing inconclusive results could improve
screening quality and program sensitivity. Nevertheless,
many European countries that have introduced population-
based screening programs based on gFOBT have already
switched to immunoassay as their screening test of choice.
As a consequence, there are fewer individuals using FIT with
an incomplete screening episode and the overall sensitivity is
higher compared with gFOBT screening programs.
On the other hand, high CRC rates among nonattenders
in further screening rounds highlight the need to better
inform our target population that successive screening is
required to avert or early detect CRC.
Variation in calculating the interval cancer rate makes
it vital that a clearly defined protocol is established for the
definition, identification, and reporting of interval cancers.
International comparisons and benchmarking of IC could
lead to better understanding of the relationship between
programs performance and screening practices.
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